<?xml version="1.0" encoding="UTF-8"?>
<p class="p">CGA and CA are reported for good AA, inhibition of N‐nitroso compounds (Kono, Shibata, Kodama, &amp; Sawa, 
 <xref rid="fsn31063-bib-0109" ref-type="ref" class="xref">1995</xref>), protection of DNA from damage (Cinkilic et al., 
 <xref rid="fsn31063-bib-0046" ref-type="ref" class="xref">2013</xref>), cardiovascular disease (Mirella et al.., 
 <xref rid="fsn31063-bib-0137" ref-type="ref" class="xref">1995</xref>), antimutagenic properties (Yamada &amp; Tomita, 
 <xref rid="fsn31063-bib-0242" ref-type="ref" class="xref">1996</xref>), scavenge of reactive oxygen species (Sato et al., 
 <xref rid="fsn31063-bib-0192" ref-type="ref" class="xref">2011</xref>), and inhibition of 8‐dehydroxy‐deoxyguanosine (involved in DNA breakage) (Kasai, Fukada, Yamaizumi, Sugie, &amp; Mori, 
 <xref rid="fsn31063-bib-0102" ref-type="ref" class="xref">2000</xref>). CGA reported as novel insulin sensitizer limits the blood glucose concentrations by inhibiting G‐6‐Pase enzyme action (Meng, Cao, Feng, Peng, &amp; Hu, 
 <xref rid="fsn31063-bib-0133" ref-type="ref" class="xref">2013</xref>).
</p>
